SkinBioTherapeutics PLC (SBTX) — Cash Flow-to-Debt Ratio
SkinBioTherapeutics PLC (SBTX) has a Cash Flow-to-Debt Ratio of -0.18x as of June 2025, meaning its operating cash flow of GBX-494.84K could theoretically repay 0% of its total liabilities (GBX2.71 Million) in one year. See SBTX current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
SkinBioTherapeutics PLC Cash Flow-to-Debt Ratio (2016–2025)
Historical debt coverage capacity for SkinBioTherapeutics PLC across 10 annual periods. Also explore SkinBioTherapeutics PLC annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for SkinBioTherapeutics PLC (2016–2025)
Year-by-year debt coverage analysis for SkinBioTherapeutics PLC. For market capitalisation and broader financial context, see SkinBioTherapeutics PLC (SBTX) total market value.
| Year | CF-to-Debt Ratio | Operating CF (GBX) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.48x | GBX-1.30 Million | GBX2.71 Million | ▲ +60.5% |
| 2024 | -1.21x | GBX-2.73 Million | GBX2.25 Million | ▲ +72.5% |
| 2023 | -4.41x | GBX-2.65 Million | GBX599.34K | ▼ -0.7% |
| 2022 | -4.38x | GBX-2.67 Million | GBX609.61K | ▼ -46.5% |
| 2021 | -2.99x | GBX-1.56 Million | GBX519.67K | ▼ -2.2% |
| 2020 | -2.93x | GBX-892.14K | GBX304.83K | ▲ +75.1% |
| 2019 | -11.77x | GBX-1.43 Million | GBX121.33K | ▼ -269.0% |
| 2018 | -3.19x | GBX-667.75K | GBX209.29K | ▲ +37.9% |
| 2017 | -5.14x | GBX-609.70K | GBX118.66K | ▼ -14711.9% |
| 2016 | -0.03x | GBX-1.17K | GBX33.64K | — |